Vogliviga GM1/0.2 Tablet in PCD pharma franchise in Hyderabad

Vogliviga GM1/0.2 Tablet in pharmaceutical manufacturing company in Mumbai

Vogliviga GM1/0.2 Tablet in diabetic pharma franchise in Pune

Vogliviga GM1/0.2 Tablet in pharma suppliers in Delhi

Vogliviga GM1/0.2 Tablet in pharma export companies in Kolkata
Vogliviga GM1/0.2 Tablet in pharma franchise opportunities in Bengaluru

Home/Products /glimepiride-1mg-voglibose-2mg-metformin-hcl-layered-tablets

Vogliviga GM1-0.2 Tablet

Composition : Glimepiride I.P. 1mg + Voglibose I.P. 0.2mg + Metformin HCL I.P. 500mg Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*15

Price : ₹1/-

Vogliviga GM1/0.2 Tablet combines Glimepiride 1mg, Voglibose 0.2mg, and Metformin 500mg in a bi-layered tablet designed to manage type 2 diabetes effectively. Glimepiride helps increase insulin release from the pancreas, Voglibose reduces post-meal blood sugar spikes by delaying carbohydrate absorption, and Metformin improves insulin sensitivity and reduces glucose production in the liver. This combination works on multiple fronts to control blood sugar levels efficiently throughout the day.

Read More

About the Product

Vogliviga GM1/0.2 Tablet combines Glimepiride 1mg, Voglibose 0.2mg, and Metformin 500mg in a bi-layered tablet designed to manage type 2 diabetes effectively. Glimepiride helps increase insulin release from the pancreas, Voglibose reduces post-meal blood sugar spikes by delaying carbohydrate absorption, and Metformin improves insulin sensitivity and reduces glucose production in the liver. This combination works on multiple fronts to control blood sugar levels efficiently throughout the day.

Common side effects may include gastrointestinal discomfort such as nausea, abdominal bloating, flatulence, and diarrhea. There is a risk of hypoglycemia, particularly if meals are skipped or dosage is not followed correctly. Long-term use of Metformin may cause vitamin B12 deficiency in some patients.

This medication is indicated for the treatment of type 2 diabetes mellitus, especially for patients who need better control of both fasting and postprandial blood glucose levels.

Not suitable for patients with type 1 diabetes, severe liver or kidney disease, or diabetic ketoacidosis. Regular monitoring of blood sugar levels is necessary during treatment. Alcohol consumption should be avoided. Follow your doctor’s advice strictly.

Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation